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Summary
The investigation of recurrent unexplained syncope is
a challenging clinical problem, as syncope remains un-
explained in up to 60% of patients referred to an emer-
gency department. In spite of the demonstrated bene-
fit of a standardised stepwise non invasive work-up,
syncope still remains undiagnosed in up to 30% of pa-
tients. The “gold standard” for the diagnostic work-up
of syncope is the correlation between clinical event and
any alteration of physiological signals, but syncope
rarely occurs during ECGmonitoring. Recent advances
in long-term cardiac monitoring techniques with im-
plantable loop recorders (ILR) offer nowadays a pow-
erful tool for the investigation of syncope as well as un-
diagnosed arrhythmias.
According to current indications, ILR is recom-
mended in patients with recurrent unexplained syn-
cope following a negative baseline work-up, who re-
quire further investigations because of syncope-related
complications. ILR can also be implanted early in the
work-up, before conventional investigations, in pa-
tients with clinical or ECG features suggesting an ar-
rhythmic syncope or to assess the contribution of
bradycardia in suspected cases of severe neurally me-
diated syncope before pacemaker implantation. Re-
cently, ILR was proposed as a novel method for atrial
fibrillation monitoring, particularly after catheter ab-
lation, but it deserves additional clinical validation due
to a high prevalence of inappropriate detection.
Key words: implantable loop recorder; unexplained
syncope; current indications; diagnostic yield; atrial fib-
rillation inappropriate detection
Introduction
Syncope is a relatively common clinical symptom ac-
counting for 3–6% of all emergency department visits
and 2% of hospital admissions [1, 2]. Despite multiple
investigations, syncope remains unexplained in up to
60% of patients referred to an emergency department
[3, 4]. Superior performance of standardised investiga-
tion strategies has been shown in patients addressed
to emergency departments for unexplained syncope [3,
5, 6]. Iglesias et al. recently pub-
lished [7] in >900 consecutive pa-
tients referred to a syncope outpa-
tient clinic that a stepwise work-up
established an aetiology in 66% and that 92% of diag-
noses were determined combining non invasive tests.
Invasive investigations poorly contributed to overall di-
agnostic yield (8%), stressing usefulness of non inva-
sive testings. In spite of the benefit of a standardised
work-up, syncope still remains undiagnosed in up to
30% of patients. Ideally, correlation between syncopal
events and any alteration of physiological signals
(ECG, blood pressure, EEG, etc.) is the “gold standard”
for the diagnostic work-up, but syncope rarely occurs
during monitoring.
Holter monitoring and external loop recorders
(ELR) have been available for many years. According to
ESC Guidelines [8], Holter monitoring is indicated
(class I recommendation) in patients with clinical or
ECG features suggesting an arrhythmia and very fre-
quent episodes (≥1/week). ELR permits extended
rhythm monitoring and ECG storage before and after
the clinical event; however, technical restrictions limit
their use to relatively short periods (10 days) making
the recording of a spontaneous event and its correla-
tion with cardiac arrhythmias unlikely. Therefore,
overall diagnostic yield of Holter monitoring in the
evaluation of syncope is relatively poor, accounting for
9% in a retrospective review [9]. Structural heart dis-
ease, impaired ejection fraction and advanced age were
found to be significant predictors of a diagnostic Holter
study, suggesting that short-term ECG monitoring re-
sults highly depend on patients’ selection. Similarly,
Sarasin et al. [10] reported a diagnostic rate of Holter
monitoring in unselected patients with unexplained
syncope as low as 6%, increasing to 12% when re-
stricted to high-risk patients with positive cardiac his-
tory or abnormal ECG.
Deception and challenges made some investigators
to modify a pacemaker to make it a subcutaneous
recorder without cardiac leads. Recent advances in
long-term cardiac monitoring techniques with im-
plantable loop recorders (ILR) offer nowadays a pow-
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erful tool for the investigation of syncope and undiag-
nosed arrhythmias.
The implantable loop recorder
Indications
The ILR is a single channel ECGmonitoring device de-
veloped to extend the monitoring period beyond 1
month in patients with unexplained syncope. Accord-
ing to ESC guidelines, the ILR is recommended in pa-
tients with recurrent unexplained syncope following
a negative baseline work-up, who require further
investigations because of complications. It can also be
implanted early before any conventional testing in
patients with clinical or ECG features suggesting an
arrhythmic syncope or to assess contribution of brady-
cardia in suspected cases of severe neurally mediated
syncope before pacemaker implantation (class II rec-
ommendations). Recently, the ILR has also been eval-
uated for atrial fibrillation (AF) monitoring before and
after ablation procedures [11, 12].
Technical characteristics
The latest version of the device (Reveal DX and XT
®
,
Medtronic Inc., USA) is rectangular, measures 62 × 19
× 8 mm and weighs 17 grams (fig. 1). A pair of sensing
electrodes built in the shell records a single-lead bipo-
lar ECG, retrievable by radiofrequency with a pro-
grammer. The battery has an estimated lifetime of
36 months. The device is inserted into subcutaneous
tissue of the left pectoral region after an incision of
approximately 2 cm in length under local anaesthesia.
Other locations include right parasternal, subcostal
and axillary areas providing, nevertheless, a signal of
lower amplitude. ECG signal is stored in a circular
buffer with a maximal storage capacity of 49.5 min
(up to 30 events) allowing detection of pauses as well as
high and low heart rate episodes. The XT version has
an algorithm for atrial tachycardia and AF detection
based on irregularities of RR intervals. Events are au-
tomatically stored (1 min for asystole, bradycardia or
ventricular tachycardia (VT), 2 min for atrial tachy-
cardia or AF) (fig. 2). The ECG memory buffer can also
be frozen using a hand-held activator after syncope has
resolved (6 min before and 1.5 min after activation for
the 3 last episodes). However, the ILR bears some lim-
itations related to overdetection of inappropriate ar-
rhythmias and underdetection of potentially malignant
arrhythmias in the auto-activation mode. Documented
causes of incorrect arrhythmia storage include over-
sensing related to sudden reductions in R wave ampli-
tude during normal sinus rhythm and arrhythmias,
undersensing by transient loss of ECG signal because
of device amplifier saturation and oversensing related
to T wave, myopotentials or other noise sources. Re-
cently, a new ILR (SJM Confirm
®
, St. Jude Medical,
Inc., USA) of similar size has been commercialised. Its
diagnostic performances have not been compared with
the Medtronic-ILR yet.
Evidence from the literature
Initial experience with the ILR
In 1995, Krahn et al. reported the first experience with
an ILR [13]. In a pilot study including 16 patients with
recurrent unexplained syncope, a pacemaker-based
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Figure 1
A shows on the left hand side an ILR (Reveal XT
®
, Medtronic Inc., USA) and its hand-held activator on the right hand side.
B shows the implantation of an ILR. After local anesthesia, a 2-cm wide incision is performed in the left subclavian region.
A 6-cm long pocket is created for insertion of the ILR.
A
B
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Figure 2
Examples of appropriate detection by the ILR. (A) shows an example of a patient-activated recording following a near syncopal event. A narrow
complex tachycardia at a rate of 167 bpm is triggered by a ventricular couplet (arrows). An electrophysiological study diagnosed runs of atrioven-
tricular nodal tachycardia. (B) shows an example of supraventricular tachycardia automatically recorded by the ILR during a syncopal event. The
overt variability of R-R intervals and the absence of QRS morphology changes (not shown) were diagnostic of paroxysmal atrial fibrillation. Normal
sinus rhythm is shown in another example in (C), followed by a 5-sec duration sinus arrest and syncope. The patient was successfully implanted
with a double-chamber pacemaker. (D) shows a syncopal sudden change in morphology and rate (240 bpm) during exercise that happened to be
a sustained ventricular tachycardia in a patient with hypertrophic cardiomyopathy and unexplained syncope.
prototype was implanted following a negative baseline
work-up including ambulatory continuous ECG moni-
toring, cardiac imaging, head-up tilt-testing (HUTT)
and electrophysiological study (EPS). Over a mean fol-
low-up of 4 months, 15 patients (94%) presented a syn-
copal event; an arrhythmia was diagnosed in 60%. In
another study [14] including 24 patients with unex-
plained syncope, a prototype was implanted after a
negative baseline work-up; among the 20 patients
(83%) who experienced syncope during follow-up, an
aetiology was established in all cases, including ar-
rhythmias in 50% and non arrhythmic causes in 50%.
Of note, individualised therapy resulted in resolution of
symptoms in 85% of patients with recurrence, empha-
sising the diagnostic and therapeutic potential of this
new technology. A few years later, a multicenter
prospective study [15] evaluated the benefit of a pro-
longed monitoring strategy in 85 patients with recur-
rent unexplained syncope after a negative initial eval-
uation. Over 11 months of follow-up, symptoms re-
curred in 68%; interestingly, an arrhythmia was
diagnosed in 42%, providing evidence for effectiveness
and safety of an ILR-based prolonged monitoring strat-
egy. Later on, Seidl et al. [16] reported the results of a
multicenter study including 133 patients with recur-
rent unexplained syncope. The setting of this study did
not include any standardised work-up. Over a mean
follow-up of 11 months, 62% of patients presented syn-
cope, establishing a symptom-rhythm correlation in
87% of cases with recurrence; overall diagnostic yield of
A
B
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ILR reached 54%.Again, an arrhythmia was diagnosed
in 44%.
Table 1 displays summary data of the most impor-
tant studies that used the ILR for the investigation of
unexplained syncope, including our experience at the
CHUV syncope outpatient clinic. On the basis of these
studies, overall diagnostic yield of ILR is about 50%.
However, these results need to be cautiously inter-
preted because diagnostic yield of ILR highly depends
upon patients’ selection and adjudication of final diag-
noses. Patients’ selection may differ depending on base-
line characteristics of study population (e.g., presence
of structural heart disease) and patient’s inclusion cri-
teria. Some studies excluded patients with typical clin-
ical presentation of neurally mediated syncope [21, 28]
or with indication for pacemaker implantation follow-
ing a positive HUTT or carotid sinus massage (CSM)
[24], decreasing consequently diagnostic yield of con-
ventional testings. Diagnostic rate also appears over-
estimated due to inclusion of normal sinus rhythm as
diagnostic during syncope recurrence. Exclusion of an
arrhythmic cause cannot be considered as diagnostic,
as sinus rhythm at time of recurrence may be associ-
ated with a broad spectrum of aetiologies such as neu-
Kardiovaskuläre Medizin 2009;12(3):85–93
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rally mediated syncope, psychogenic pseudo-syncope
and hypotensive or neurological disorders. Proportion
of sinus rhythm considered as diagnostic is about 20%
for an average diagnostic yield of about 50%. Although
some authors have considered the ILR as the gold stan-
dard for syncope management, an unexpectedly high
proportion of patients (5–10%) failed to activate the de-
vice. The newer ILR generation has eased the hand-
held activation, which should decrease failure rate.
ILR as a tool to identify mechanisms of syncope
The ILR has been used for elucidation of mechanisms
in subgroups of high-risk patients with unexplained
syncope. In the ISSUE study, 111 patients with recur-
rent unexplained syncope, absence of structural heart
disease and normal baseline ECG were implanted with
an ILR and followed up for 3–15 months [17]. Interest-
ingly, recurrence rate (34%) and diagnostic yield of ILR
(29% vs 28%, respectively) were similar in patients
with isolated syncope (no structural heart disease and
negative complete work-up) and HUTT-positive pa-
tients (no structural heart disease and positive HUTT).
The most frequent cause of recurrence in both groups
(46% and 62%, respectively) was prolonged asystolic
pauses (15 sec on average) preceded by progressive
bradycardia or tachycardia-bradycardia episodes.
These findings suggest a common mechanism and out-
come in both groups. The cause appeared to be a neu-
rally mediated syncope involving reflex bradycardia. In
another subset of 52 patients with bundle branch block
and negative EPS [18], syncope only recurred in 22 pa-
tients (42%) over 3–15 months of follow-up yielding a
diagnosis in 37%. 90% of recurrent events showed pro-
longed asystolic pauses mainly attributable to parox-
ysmal AV block (
2
/
3
of patients). In the last subset of 35
patients with mild structural heart disease (mean left
ventricular ejection fraction 47 ± 17%) and negative
EPS [19], syncope recurred in only 17% and presyncope
in 37% over 3–15 months of follow-up, yielding a diag-
nosis in 40% of patients. Most recurrences were due
to bradycardia with long pauses while sustained VT
remain unlikely (1 case), stressing that patients with
mild structural heart disease and negative EPS show
favorable mid-term outcome. In a prospective study by
Solano et al. [20], 103 patients (structural heart dis-
ease in 37%) with severe unexplained syncope were
followed during 13 months. Syncope recurrence (about
50%) and ILR diagnostic yield (58% vs 45%, respec-
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Table 1
Diagnostic yield of ILR in patients with recurrent unexplained syncope.
Authors Patients Mean age Mean Structural Baseline non Diagnostic Patients with Activation
(n) (years) follow-up) heart invasive yield
3
(%) normal sinus failure (%)
(months disease (%) work-up rhythm (%)
Krahn et al. [13] 16 57 13 50 Complete
1
94 19 0
Krahn et al. [15] 85 59 11 62 Incomplete
2
59 34 9
Seidl et al. [16] 133 56 11 40 Incomplete
2
54 30 8
Nierop et al. [28] 35 65 11 29% BBB Incomplete
2
57 29 11
Krahn et al. [21] 30 68 12 43 Incomplete
2
47 3 3
Moya et al. [17] 111 64 10 32 Complete
1
29 11 5
Brignole et al. [18] 52 71 3–15 54 Complete
1
37 4 6
Menozzi et al. [19] 35 66 16 100 Complete
1
40 17 20
Krahn et al. [22] 206 57 ≥6 33 Incomplete
2
64 31 5
Solano et al. [20]
4
38 69 13 100 (68% BBB) Complete
1
58 5 4
65 69 13 0 Complete
1
46 17 4
Lombardi et al. [33] 34 60 7 9 Complete
1
50 18 13
Farwell et al. [24] 103 74 17 48% CAD Complete
1
43 23 5
Brignole et al. [26] 392 66 9 14 Complete
1
27 9 ?
Kothari et al. [31] 18 11 18 11 Complete
1
50 6 ?
Yeung et al. [32] 34 11 15 24 Incomplete
2
56 32 6
Pezawas et al. [25] 70 55 16 47 Incomplete
2
86 39 ?
Iglesias et al. [7] 63 58 16 14 Complete
1
57 24 3
Total 1520 58 13 39 Complete
1
: 61% 53 19 7
BBB = bundle branch block; CAD = coronary artery disease; n = number.
1
Complete means that patients underwent a complete non invasive work-up including tilt-table testing, carotid sinus massage and testing
for orthostatic hypotension prior to ILR implantation.
2
Incomplete means that part or all of the non invasive work-up was not performed prior to ILR implantation.
3
Diagnostic yield is defined as the proportion of diagnostic tests divided by the number of performed tests.
4
Note that this study includes two sets of patients, one with and the other one without structural heart disease.
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tively) were similar in patients with or without struc-
tural heart disease; however, paroxysmal AV block and
tachycardia were significantly more common in pa-
tients with, whereas normal sinus rhythm, sinus
bradycardia and sinus arrest were more frequent in pa-
tients without structural heart disease. These findings
highlight different underlying mechanisms of syncope
depending on the presence or absence of a structural
heart disease.
ILR as an alternative to conventional testing
Krahn et al. [21] randomised 66 patients with unex-
plained syncope to conventional testing (ELR, HUTT,
EPS) or to 1-year monitoring with an ILR. A final di-
agnosis was established in 52% of patients investigated
with an ILR, while conventional work-up yielded a di-
agnosis in only 20%. Importantly, superiority of the
ILR-based strategy over conventional testing had been
strengthened by excluding patients whose cause was
likely vasovagal. Results might have been different for
unselected patients. Benefit of prolonged monitoring
strategy was also suggested in another study [22] in-
cluding 206 patients implanted with an ILR because of
unexplained syncope after a negative conventional
work-up including HUTT and EPS. After 6 months,
overall diagnostic yield of ILR achieved 64%, including
23% of arrhythmias. Farwell et al. [23, 24] compared
the use of ILR with conventional testings for evalua-
tion of 201 consecutive patients without structural
heart disease presenting to an emergency department
for recurrent unexplained syncope. Eligible patients
underwent a baseline investigation including CSM and
HUTT; those without indication for pacemaker im-
plantation were randomized to either conventional
testing (Holter monitoring, ELR, EPS) or ILR implan-
tation. Diagnostic rate was again significantly higher
in ILR patients as compared to conventionally investi-
gated patients (43% vs 7%, respectively) over 17
months of follow-up. Moreover, patients in the ILR arm
underwent fewer post-randomisation investigations
and hospitalisation days. Time to second syncope was
significantly longer in the ILR arm with subsequent re-
duction in syncopal events and improvement in quality
of life. No statistically significant difference in overall
mortality (12%) and global costs savings was noted be-
tween the two investigation strategies. Nevertheless,
as stated above, patients were highly selected, pre-
venting any conclusion about usefulness of ILR in an
unselected population.
In a recent prospective study by Pezawas et al.
[25], an ILR was implanted in 70 patients with recur-
rent unexplained syncope following a negative baseline
investigation including CSM, HUTT, echocardiogram
and Holter monitoring. Interestingly, half of the pa-
tients (47%) had documented structural heart disease.
Syncope recurrence rate during follow-up was similar
in patients with and without structural heart disease
(about 85%); an arrhythmia was documented in half of
the cases in both groups. Interestingly, presence of a
major depressive disorder was predictive of early syn-
copal recurrence, while documented structural heart
disease was poorly predictive of arrhythmias. Finally,
in the ISSUE-2 study [26], 392 patients with >2
episodes of suspected neurally mediated syncope were
implanted with an ILR and followed until the first doc-
umented recurrence. Patients with significant ECG or
cardiac abnormalities, orthostatic hypotension and
carotid sinus hypersensitivity had been excluded. Re-
currence occurred in 33% after a year of follow-up. The
ILR provided an ECG tracing in only 26% because 7%
failed to activate the device. Patients with recurrence
underwent an ILR-based therapy including pacemaker
and defibrillator implantation, catheter ablation, anti-
arrhythmic drug or no specific therapy when no ar-
rhythmia had been detected at time of recurrence. The
1-year syncope recurrence was significantly lower in
the ILR-based therapy arm compared with patients
without specific therapy (10% vs 41%, respectively).
Authors concluded that an ILR-based strategy and
therapy was a reasonable alternative to usual man-
agement of patients with suspected neurally mediated
syncope. However, treatment groups had not been ran-
domised, preventing any conclusions on the therapeu-
tic potential of the ILR.
Unexpected therapeutic properties
of implantable devices
A placebo effect of implantable devices on syncope re-
currence has been well documented over the last
decade. In the VPS II trial [27], 100 patients with re-
current HUTT-positive syncope were implanted with a
dual chamber pacemaker and randomised to inactive
(ODO) or active (DDD) pacing mode. Over a follow-up
of 6 months, syncope recurred only in 42% and 33% of
active and inactive groups, respectively, suggesting
that implantation itself dramatically reduced syncope
recurrence. Significant reduction in syncope rate is also
a common finding following ILR implantation. Nierop
et al. [28] reported resolution of symptoms in 17% after
ILR implantation. In the different substudies of the
ISSUE trial, patients with a mean of ≥2 syncopal
episodes during the last 2 years prior to randomisation
experienced a decrease in syncope recurrence by a fac-
tor of 2 [18], 3 [17] and 5 [19], respectively, in the year
following ILR implantation. Moreover,
2
/
3
of ILR-im-
planted patients included in the ISSUE 2 trial [26],
with a median of 4 syncopal events during the last
2 years prior to implantation, did not experience re-
currence over a median follow-up of 9 months, high-
lighting the potential placebo effect of ILR in patients
suffering from syncope. The way that ILR potential
placebo effect may affect overall diagnostic rate of ILR
studies needs to be evaluated by future formal ran-
domised placebo-controlled studies.
Kardiovaskuläre Medizin 2009;12(3):85–93
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Cost-effectiveness of ILR
One trial [29] evaluated the cost implications of a pro-
longed monitoring strategy in the investigation of un-
explained syncope. 60 patients with unexplained syn-
cope were randomised to either conventional testing
(ELR, HUTT, EPS) or 1-year ILR monitoring. The lat-
ter yielded a diagnosis in 47%, while conventional test-
ing established a diagnosis in 20%. Although the cost
was greater in the ILR monitoring group compared
with conventional testing group, cost per diagnosis was
significantly reduced because of the greater diagnostic
yield, suggesting superiority in term of cost-effective-
ness of a primary ILR-based strategy. However, some
limitations have to be mentioned as patients with sus-
pected vasovagal syncope or left ventricular dysfunc-
tion had been excluded, preventing any conclusion
about the poor diagnostic yield of HUTT and EPS.
ILR as a tool for the investigation of epilepsy
The ILR has also been used for evaluation of generali-
sed tonic-clonic seizures. The specific myopotential pat-
tern observed during generalised seizures because of
diffuse muscle contractions is readily seen by the ILR
and appears different from pattern seen with either
convulsive syncope or non-generalised seizures. In a
study [30] including 14 patients with refractory docu-
mented epilepsy, an ILR was implanted as part of a
study protocol evaluating cardiac rhythm abnormali-
ties in patients at risk for sudden death. Tonic-clonic
seizure episodes were detected by the ILR in 6 patients
(43%). However, the use of ILR for diagnosis of gene-
ralised seizure episodes bears some limitations as rapid
frequency of myopotential artifacts may exceed the
nonprogrammable bandpass filter of the device (32 Hz),
preventing any automatic detection. The inability to
automatically capture these high-frequency myopoten-
tials highlights that their absence upon ILR interroga-
tion can not formally exclude seizures, except when
manually activated.
ILR in pediatric population
Studies about the use of ILR in paediatric patients are
limited. No consensual guidelines are currently avail-
able, but ILR is recommended after a negative conven-
tional work-up in children with structural heart dis-
ease, family history of sudden death, symptoms associ-
ated with exercise, chest pain, palpitations or ECG
suggesting an arrhythmia [8]. In one study [31], the di-
agnostic yield of ILR reached 50%. However, ILR
showed some limitations because of an imperfect auto-
matic algorithm leading to episodes of auto-activation
failure as well as frequent false-positive activations re-
lated to muscle artefacts that may have over-recorded
arrhythmias. In another recent study [32], ILR im-
plantation showed unexpected therapeutic properties,
leading to resolution of symptoms in about 50% of im-
planted patients.
Experience at the CHUV syncope outpatient
clinic
The CHUV syncope outpatient clinic investigated over
the last 9 years >1000 patients referred for unex-
plained syncope [7]. Patients underwent a standard-
ised work-up including HUTT followed by supine and
upright CSM. Structural heart disease was ruled out
on the basis of patient’s history, physical examination
and 12-lead ECG. EPS was performed in patients with
an underlying cardiac disease or in patients whose ini-
tial non invasive evaluation was negative, and who re-
quired further investigations. An ILR was proposed to
136 patients following a negative work-up because of
syncope-related complications; 57 patients accepted im-
plantation (5% of total population). 6 additional pa-
tients with an indication other than syncope were also
implanted. Patients had a mean age of 58 ± 18 years
and 35% were women. Ischaemic heart disease was
documented in 6%. Sudden syncope was the presenta-
tion mode in 38%. Patients were followed up over a
mean of 483 ± 287 days after ILR implantation. 1 pa-
tient was lost to follow-up. Table 2 shows the final
causes of syncope as established by the ILR. Overall,
the ILR yielded a diagnosis in 57% of patients, while
syncope remained unexplained in 43%. An arrhythmia
was diagnosed in 33%, with equal proportion of sick
sinus syndrome (19%) and supraventricular tachycar-
dia (14%). Interestingly, the ILR helped to diagnose in-
termittent hypotensive disorders in 25%. Remaining
causes included epilepsy (11%), situational (3%) and
psychogenic pseudo-syncope (3%). It is noteworthy that
2 among 4 of the patients diagnosed with supraven-
tricular arrhythmias had undergone a negative EPS
prior to ILR implantation. Similarly, 3 patients diag-
nosed with epilepsy had a negative neurological evalu-
ation including electroencephalogram before implan-
tation. These results confirm the incremental benefit
of ILR implantation in patients with unexplained
syncope after a negative standardised work-up. Our
experience with newer generation of ILR also tends to
Kardiovaskuläre Medizin 2009;12(3):85–93
Table 2
Final causes of syncope as diagnosed with the ILR.
Cardiac arrhythmias 12 (33)
Sick sinus syndrome 7 (19)
Supraventricular tachycardia 5 (14)
Atrial fibrillation 3 (8)
AV nodal reentrant tachycardia 2 (6)
Hypotensive disorder 9 (25)
Vasovagal 9 (25)
Epilepsy 4 (11)
Psychogenic pseudo-syncope 1 (3)
Situational 1 (3)
Unmarked data are n (%).
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confirm the current limitations of the AF detection
algorithm based on irregularities of RR intervals.
Figure 3 shows examples of inappropriate detection of
AF. These limitations emphasise the need for further
technical improvements to make ILR a gold standard
for AF diagnosis.
ILR as a tool for the monitoring of atrial
fibrillation
The ILR has recently been proposed for AF monitoring.
Montenero et al. [11] reported the results of a pilot
study including 9 candidates for ablation with frequent
and highly symptomatic episodes of drug-refractoryAF.
Six patients were implanted with an ILR and moni-
tored one month before and six months after the pro-
cedure. Overall, 178 events were recorded including
30% of patient-activated and 70% of automatic acti-
vated events. Of note,
1
/
3
of recordings were inappro-
priate, largely due to premature atrial or ventricular
beats. In a recent study [12] including 45 ILR-im-
planted patients with drug refractory paroxysmal AF,
asymptomatic episodes significantly increased from
about 3% before to 42% after ILR implantation,
emphasising the need for accurate assessment of ar-
rhythmia burden following catheter ablation. However,
same authors reported an unexpectedly high rate (69%)
of inappropriate recording, limiting the use of ILR for
arrhythmia burden measurement. These results tend
to confirm the need for further improvements of AF de-
tection algorithms before considering ILR as a method
of choice for AF monitoring.
Conclusion
Growing evidence tends to support the incremental
benefit of ILR in the investigation of recurrent unex-
plained syncope. The mean diagnostic yield of ILR re-
ported in the literature is about 50–60% but strongly
Kardiovaskuläre Medizin 2009;12(3):85–93
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Figure 3
Inappropriate detection of AF. Shown in (A) an example of inappropriate detection of AF triggered by irregularities of R-R intervals due to frequent
ventricular premature beats (arrows). (B) shows another example of inappropriate detection of AF due to high-frequency muscle noise detection.
The patient was exercising at that time wearing a backpack.
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depends upon study settings and patients’ inclusion cri-
teria. When limited to selected patients with severe un-
explained syncope after a complete baseline non inva-
sive work-up, our own experience confirmed these find-
ings with a diagnosis yield of 57%. Whether the ILR
may become the gold standard for the diagnosis of AF
and follow-up of patients undergoing catheter ablation
needs additional clinical validation. However, prelimi-
nary results report a high prevalence of inappropriate
detection limiting reliability of the device to date.
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